Interview: Thomas Würdinger – Head of Neuro-Oncology at VUMC, Galenus prize winner, VU Medical Center, The Netherlands
11.11.2015
Related Interviews
Italy / Gilead's Valentino Confalone on Eliminating Viral Hepatitis by 2030, HIV Pipeline Potential, & the Future of CAR-T
Can you begin by commenting on Gilead’s footprint in Italy, a country where the company has been present for just two decades? Even though it is relatively young, Gilead is…
Mohamed Mostafa – Vice President and General Manager Saudi Arabia &…
IQVIA Vice President and General Manager Saudi Arabia & Egypt Mohamed Mostafa gives his expert insights into the transformation of the Saudi pharma market in recent years, covering everything from…
Italy / Gilead's Valentino Confalone on Eliminating Viral Hepatitis by 2030, HIV Pipeline Potential, & the Future of CAR-T
Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in…
Australia / Artificial Intelligence Can Save Pharmacovigilance
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
China / Emerging Pharmacovigilance Framework Ensuring Safe COVID-19 Vaccines
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
Spain / 5 Key Industry Trends 2021
According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends…
